BLUE 400 from ZEISS supports intraoperative differentiation between diseased and healthy tissue. It was the only microscope integrated fluorescence module to prove its efficiency in a successfully conducted Phase III multi-center study.
According to a 2015 study by Esteves et al., high-grade gliomas (grades III–IV) are the most common brain tumors in Europe, with an incidence of 3.13 per 100,000 residents. The extent of tumor resection is a major prognostic factor for survival.3 Studies show that resection of at least 98% of the tumor tissue is required to significantly impact the survival rate. A randomized controlled trial (RCT) study by Stummer et al. in 2006 showed that the probability of complete resection of the tumor was significantly increased when using 5-ALA fluorescence (5-aminolevulinic acid) (65% vs. 37%, p<0.0001)